Thermo Fisher Scientific

Dover, Delaware – October 06, 2026 -- The Digital CMC Consortium has launched as a new industry collaboration aimed at the end-to-end digitalization of Chemistry, Manufacturing, and Controls (CMC) processes in drug development. Founding participants include Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship's Pioneering Medicines, Stellix, ZS Associates, and QbDVision.

Consortium targets legacy PDF-based workflows that bottleneck drug development

The CMC phase of pharmaceutical development remains tethered to manual, document-based processes that treat PDF tables as the source of truth, despite rapid advances in drug discovery and clinical trial digitization elsewhere in the industry. The Consortium aims to convert static CMC knowledge into reusable, interoperable digital assets to improve speed, quality, and regulatory confidence.

Sheridan, Wyo. – October 05, 2026 -- The global in vitro diagnostics (IVD) quality control market is set to climb from $1.7 billion in 2026 to $2.2 billion by 2031, a 5.3% compound annual growth rate, according to a new study by Wissen Research.

Rising testing volumes and regulatory pressure push labs toward automated QC

Growth is driven by expanding testing complexity across clinical chemistry, immunoassay, hematology, and molecular diagnostics, combined with tightening regulatory requirements such as CLIA in the United States. Laboratories are increasingly adopting internal quality controls, third-party control materials, and external quality assessment programs as standard practice.

Sheridan, Wyoming – – September 22, 2026 -- The global lateral flow assay market is set to expand from $11.04 billion in 2026 to $16.37 billion by 2031, a compound annual growth rate of 8.2%, according to a new study by Wissen Research.

Delray Beach – September 20, 2026 -- The global Laboratory Information Management System (LIMS) market is projected to grow from USD 3.26 billion in 2026 to USD 5.84 billion by 2031, a compound annual growth rate of 12.4%, according to MarketsandMarkets.

Rising test volumes force labs to digitize workflows

The US Centers for Disease Control and Prevention estimates that healthcare professionals order more than 14 billion laboratory tests annually across over 266,000 CLIA-certified laboratories nationwide. In India, the RMLIMS platform recorded complete blood count testing rise from 236,289 to 331,541 procedures between 2023 and 2025, while molecular testing volumes climbed from 728 to 1,236 over the same period.

Delray Beach, Fla. – September 16, 2026 -- The global cryovials market is projected to grow from $0.24 billion in 2026 to $0.31 billion by 2031, expanding at a compound annual growth rate of 5.5%, according to MarketsandMarkets.

Cell and gene therapy demand drives fastest-growing application segment

The cell and gene therapy segment is set to register the highest CAGR among applications at 8.0%, fueled by expanding commercialization of CAR-T cell therapies, stem cell treatments, and gene-modified therapies. These advanced therapies require secure cryogenic storage across collection, processing, manufacturing, transportation, and administration to preserve cell viability. Manufacturers scaling from clinical to commercial production are prioritizing sterile, barcoded cryovials with secure closure systems compatible with automated storage.

Delray Beach, Fla. – September 15, 2026 -- The global biological safety cabinet market is projected to grow from USD 0.26 billion in 2026 to USD 0.36 billion by 2031, a 6.6% CAGR, according to MarketsandMarkets.

Pharma investment and biosafety upgrades drive containment equipment demand

Expansion of drug discovery, biologics, cell and gene therapy, and vaccine development is pushing laboratories to replace aging cabinets with certified, higher-performance containment systems. Rising biosafety requirements for handling infectious agents and hazardous materials are accelerating both new installations and equipment upgrades across clinical, academic, and pharmaceutical labs.

Delray Beach, Fla. – September 11, 2026 -- The global laboratory mixers market is projected to reach USD 2.74 billion by 2031, up from USD 2.27 billion in 2026, growing at a compound annual rate of 3.5%, according to a new report from MarketsandMarkets.

Asia Pacific to outpace global growth with 6.5% CAGR

The Asia Pacific region is forecast to grow at a 6.5% CAGR through 2031, outpacing the global average, driven by expanding research laboratory capacity and biopharmaceutical development. North America is expected to retain the largest overall market share in 2031, supported by a dense concentration of research universities, biomedical institutes, contract research organizations, and clinical laboratories that maintain a large installed base of vortex mixers, magnetic stirrers, shakers, and thermal mixers.

Delray Beach, Fla. – – September 10, 2026 -- The global laboratory glassware market is projected to grow from USD 7,630 million in 2026 to USD 9,170 million by 2031, a compound annual growth rate of 4.0%, according to new data from MarketsandMarkets.

Plasticware commands 68% of market share as labs shift away from traditional glass

Plasticware, which includes pipettes, beakers, racks, bottles and containers, accounted for 68% of the laboratory glassware market in 2025. Within this segment, polyethylene products are forecast to post the fastest growth rate in the category, at 4.5% CAGR between 2026 and 2031. The shift reflects laboratory demand for lightweight, shatter-resistant, single-use consumables that improve contamination control and reduce costs across pharmaceutical, biotechnology, contract research organization and food & beverage labs.

Delray Beach, Fla. – September 08, 2026 -- The global clinical trial services market will grow from $66.20 billion in 2026 to $97.41 billion by 2031, expanding at a compound annual growth rate of 8.0%, according to MarketsandMarkets.

North America commands 45% of the market as CRO density drives outsourcing demand

North America held the largest regional share in 2025, roughly 45%, anchored by a dense concentration of contract research organizations and established pharmaceutical R&D spending. Phase III trials accounted for the largest service share in 2025 at approximately 39.5%, reflecting the higher volume of outsourced work their complexity demands. Small molecules led by modality with a 50.5% share in 2025, supported by a large installed pipeline of drug candidates.